RapidAI

Executive Summary

RapidAI is a leading clinical AI company headquartered in San Mateo, California, focused on delivering deep decision support for critical disease states across neurovascular, cardiac, vascular, and radiology service lines. Founded in 2012, the company has built an enterprise platform with multiple FDA-cleared modules that provide actionable insights to enhance assessment and improve patient outcomes while driving operational efficiency. Leveraging extensive clinical validation, RapidAI's solutions are designed to transform care by reducing time to diagnosis, standardizing treatment decisions, and enabling faster, more accurate interventions. The company's modular, scalable platform positions it well to capture share in the rapidly growing AI diagnostics market, supported by strong regulatory clearances and a focus on high-acuity conditions where clinical impact is greatest. With a robust portfolio of FDA-cleared applications and a growing install base in hospitals and health systems, RapidAI is poised for continued expansion. The company benefits from secular tailwinds in digital health adoption, particularly in stroke, pulmonary embolism, and cardiac imaging. Its proven ability to reduce care variability and improve outcomes makes it an attractive partner for healthcare organizations seeking to integrate AI into clinical workflows. As the company scales its commercial efforts and extends into adjacent disease areas, it is well positioned to solidify its leadership in the clinical AI space. RapidAI's private status and strong product-market fit suggest significant upside potential, though near-term catalysts will be critical to accelerating growth and driving valuation.

Upcoming Catalysts (preview)

• Q3 2026New FDA clearance for a cardiac or vascular module75% success
• Q3 2026Strategic partnership with a major health system or imaging OEM65% success
• Q3 2026Series C or late-stage funding round to support international expansion60% success